Cargando…

A Retrospective Cohort Study of the Potency of lipid-lowering therapy and Race-gender Differences in LDL cholesterol control

BACKGROUND: Reasons for race and gender differences in controlling elevated low density lipoprotein (LDL) cholesterol may be related to variations in prescribed lipid-lowering therapy. We examined the effect of lipid-lowering drug treatment and potency on time until LDL control for black and white w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turner, Barbara J, Hollenbeak, Christopher S, Weiner, Mark, Tang, Simon SK
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197552/ https://www.ncbi.nlm.nih.gov/pubmed/21961563 http://dx.doi.org/10.1186/1471-2261-11-58

Ejemplares similares

Lipid-lowering therapies and achievement of LDL-cholesterol targets
por: Rizzo, Manfredi, et al.
Publicado: (2012)

New and emerging lipid-modifying drugs to lower LDL cholesterol
por: Kosmas, Constantine E, et al.
Publicado: (2021)

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?
por: Khan, Safi U., et al.
Publicado: (2020)

Implications of the obesity epidemic for lipid-lowering therapy: Non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target
por: Hoenig, Michel R
Publicado: (2008)

Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients
por: Karalis, Dean G., et al.
Publicado: (2012)

Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides
por: Mallon, Patrick W G, et al.
Publicado: (2021)

When LDL Cholesterol Is Not LDL Cholesterol: LpX, A Clinical Lesson
por: Huygen, Lisa P.M., et al.
Publicado: (2022)

Short-term LDL cholesterol-lowering efficacy of plant stanol esters
por: Hallikainen, Maarit, et al.
Publicado: (2002)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
por: Storey, Benjamin C., et al.
Publicado: (2018)

LDL-cholesterol to HDL-cholesterol ratio discordance with lipid parameters and carotid intima-media thickness: a cohort study in China
por: Lou, Yanmei, et al.
Publicado: (2020)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Lower plasma cholesterol, LDL-cholesterol and LDL-lipoprotein subclasses in adult phenylketonuria (PKU) patients compared to healthy controls: results of NMR metabolomics investigation
por: Cannet, Claire, et al.
Publicado: (2020)

A Statistical Study of Serum Cholesterol Level by Gender and Race
por: Prasad Tharu, Bhikhari, et al.
Publicado: (2017)

LDL-Cholesterol Lowering of Plant Sterols and Stanols—Which Factors Influence Their Efficacy?
por: Trautwein, Elke A., et al.
Publicado: (2018)

Targeting LDL Cholesterol With LNA
por: Krieg, Arthur M
Publicado: (2012)

Cellular itinerary of LDL cholesterol
por: Vance, Jean E.
Publicado: (2022)

Discordance of Non-HDL and Directly Measured LDL Cholesterol: Which Lipid Measure is Preferred When Calculated LDL Is Inaccurate?
por: Baruch, Lawrence, et al.
Publicado: (2013)

Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets: Lipid-lowering combination therapy
por: Masana, Lluís, et al.
Publicado: (2020)

Historical Review of the Use of Relative Risk Statistics in the Portrayal of the Purported Hazards of High LDL Cholesterol and the Benefits of Lipid-Lowering Therapy
por: Diamond, David M, et al.
Publicado: (2023)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

Friedewald’s equation for calculating LDL-cholesterol: Is it the time to say “Goodbye” and adopt direct LDL cholesterol methods?
por: Khan, Sikandar Hayat, et al.
Publicado: (2019)

Correction: Historical Review of the Use of Relative Risk Statistics in the Portrayal of the Purported Hazards of High LDL Cholesterol and the Benefits of Lipid-Lowering Therapy
por: Diamond, David M, et al.
Publicado: (2023)

LDL–cholesterol transport to the endoplasmic reticulum: current concepts
por: Pfisterer, Simon G., et al.
Publicado: (2016)

Age- and Gender-Related Differences in LDL-Cholesterol Management in Outpatients with Type 2 Diabetes Mellitus
por: Russo, Giuseppina, et al.
Publicado: (2015)

Postprandial decrease in LDL-cholesterol in men with metabolic syndrome
por: Skoczyńska, Anna, et al.
Publicado: (2015)

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
por: Jetty, Vybhav, et al.
Publicado: (2017)

Standardization of Apolipoprotein B, LDL‐Cholesterol, and Non‐HDL‐Cholesterol
por: Contois, John H., et al.
Publicado: (2023)

Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low"
por: Fazio, Sergio, et al.
Publicado: (2001)

Dose-dependent LDL-cholesterol lowering effect by plant stanol ester consumption: clinical evidence
por: Laitinen, Kirsi, et al.
Publicado: (2012)

Urinary Tartaric Acid, a Biomarker of Wine Intake, Correlates with Lower Total and LDL Cholesterol
por: Domínguez-López, Inés, et al.
Publicado: (2021)

Cholesterol-Lowering Activity of Vitisin A Is Mediated by Inhibiting Cholesterol Biosynthesis and Enhancing LDL Uptake in HepG2 Cells
por: Yuan, Yangbing, et al.
Publicado: (2023)

Inclusion of Almonds in a Cholesterol-Lowering Diet Improves Plasma HDL Subspecies and Cholesterol Efflux to Serum in Normal-Weight Individuals with Elevated LDL Cholesterol
por: Berryman, Claire E, et al.
Publicado: (2017)

Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region
por: Lee, Zhen-Vin, et al.
Publicado: (2021)

The effects of serum cholesterol, LDL, and HDL levels on gallstone cholesterol concentration
por: Atamanalp, S. Selcuk, et al.
Publicado: (2013)

Endothelial Function in Dyslipidemia: Roles of LDL-Cholesterol, HDL-Cholesterol and Triglycerides
por: Higashi, Yukihito
Publicado: (2023)

LDL cholesterol estimation in patients with the metabolic syndrome
por: Gazi, Irene, et al.
Publicado: (2006)

LDL Cholesterol and Dysglycemia: an Intriguing Physiological Relationship
por: Merino, Jordi, et al.
Publicado: (2020)

LDL-Cholesterol and Platelets: Insights into Their Interactions in Atherosclerosis
por: Gąsecka, Aleksandra, et al.
Publicado: (2021)

Addressing dyslipidemic risk beyond LDL-cholesterol
por: Tall, Alan R., et al.
Publicado: (2022)

LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China)
por: Zheng, Wen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7sd9jndi8lpl861u7s14arlplg